Skip to main content
Praxis Precision Medicines, Inc. logo

Praxis Precision Medicines, Inc. — Investor Relations & Filings

Ticker · PRAX ISIN · US74006W2070 US Manufacturing
Open in API
Filings indexed 458 across all filing types
Latest filing 2024-08-01 Director's Dealing
Country US United States of America
Listing US PRAX

About Praxis Precision Medicines, Inc.

https://praxismedicines.com/

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company that develops therapies for central nervous system (CNS) disorders. The company's methodology involves translating insights from genetic epilepsies into treatments for conditions characterized by neuronal excitation-inhibition imbalance. Praxis employs a genetics-focused approach, utilizing translational tools and patient-guided development strategies to advance its portfolio. The developmental pipeline includes several clinical-stage assets and numerous early-stage programs designed to address complex brain disorders.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2024-08-01 English
OWNERSHIP DOCUMENT
Director's Dealing
2024-08-01 English
OWNERSHIP DOCUMENT
Director's Dealing
2024-08-01 English
OWNERSHIP DOCUMENT
Director's Dealing
2024-08-01 English
SC 13G
Major Shareholding Notification
2024-07-02 English
FORM S-8 POS
Transaction in Own Shares Classification · 100% confidence The document is a Post-Effective Amendment No. 1 to Form S-8 Registration Statement filed with the SEC by Praxis Precision Medicines, Inc. It relates to the amendment and restatement of the company's stock option and incentive plans, specifically increasing shares available under the 2020 Plan and reducing shares under the Inducement Plan. The document includes legal and indemnification provisions, references to SEC rules and filings, and is clearly a registration statement amendment for securities issuance purposes. Form S-8 is used for registering securities to be offered under employee benefit plans, which falls under the category of Transaction in Own Shares (POS) as it relates to share issuance under stock plans. The document is not an annual report, earnings release, or other financial report but a capital/financing related SEC filing. Therefore, the appropriate classification is POS (Transaction in Own Shares). The document length and content confirm it is the filing itself, not just an announcement or certification.
2024-06-10 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.